Autogene cevumeran

奥基司米瑞

Report date: 2026/05/13 15:37:32

Base Information

Drug NameAutogene cevumeran
Drug Alias NameIndividualized Neoantigen Specific immunotherapyiNeSTIVAC_M_uIDPersonalized cancer vaccine RO7198457RO-7198457 +[10] 
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccine > personalized mRNA cancer vaccines
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsKidney Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[21] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBiontech Se
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer CenterF. Hoffmann-La Roche LtdBiontech Se +[4] 
Inactive CompaniesBiontech Rna Pharmaceuticals Gmbh
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsKidney Neoplasms +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A